Sloand 2004.

Methods	Randomised, placebo‐controlled trial
Participants	25 adult men and women with ESRD (on either haemodialysis or peritoneal dialysis) who also had RLS by IRLSSG criteria, recruited from the dialysis units of a single medical centre (USA)
Interventions	Active: IV iron dextran given as: 30 mg test dose over 3 min, followed by 970 mg (in 485 mL volume) over 3 hrs if no reaction to the test dose Placebo: sodium chloride given in the same volume and with the same timing as the intervention group
Outcomes	ferritin, hematocrit, gastrointestinal side effects, University of Rochester severity score (10‐point scale, where 0 = none, 10 = bad) at 0, 1, 2, 4 weeks
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified
Allocation concealment (selection bias)	Low risk	Randomisation appears to have been performed by pharmacy
Blinding (performance bias and detection bias) All outcomes	Low risk	Medication and tubing covered with opaque sleeve to conceal treatment condition
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Two placebo participants dropped out after infusion; Figure 1 reports data on all 14 placebo participants although use of last observation carried forward not explicitly stated
Selective reporting (reporting bias)	Unclear risk	No study protocol available
Other bias	Unclear risk	Baseline imbalance of 2 points in RLS severity score; there was also a broader range of scores in the treated group; imbalance in duration of dialysis